Mayinglong Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Mayinglong Pharmaceutical Group kazanç ve gelirin sırasıyla yıllık 18.9% ve 14.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 18.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 14.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

18.9%

Kazanç büyüme oranı

18.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.8%
Gelir büyüme oranı	14.4%
Gelecekteki özkaynak getirisi	14.7%
Analist kapsamı	Low
Son güncelleme	19 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

Oct 01

What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You

Aug 19

Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 24

Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet

Jun 19

Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 07

Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel

Mar 22

Kazanç ve Gelir Büyüme Tahminleri

SHSE:600993 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	4,840	767	672	748	2
12/31/2025	4,276	687	501	628	2
12/31/2024	3,727	573	381	437	2
9/30/2024	3,482	482	543	845	N/A
6/30/2024	3,424	474	602	864	N/A
3/31/2024	3,259	453	497	754	N/A
12/31/2023	3,137	443	356	604	N/A
9/30/2023	3,194	481	18	162	N/A
6/30/2023	3,245	488	270	396	N/A
3/31/2023	3,416	529	286	388	N/A
12/31/2022	3,532	479	267	342	N/A
9/30/2022	3,640	513	600	665	N/A
6/30/2022	3,644	482	547	607	N/A
3/31/2022	3,473	485	522	580	N/A
12/31/2021	3,385	465	532	597	N/A
9/30/2021	3,587	457	81	144	N/A
6/30/2021	3,479	439	-13	55	N/A
3/31/2021	3,317	427	92	158	N/A
12/31/2020	2,792	419	238	283	N/A
9/30/2020	2,518	396	651	687	N/A
6/30/2020	2,411	378	543	582	N/A
3/31/2020	2,431	336	425	468	N/A
12/31/2019	2,705	360	445	492	N/A
9/30/2019	2,528	349	190	233	N/A
6/30/2019	2,400	290	344	374	N/A
3/31/2019	2,311	241	355	385	N/A
12/31/2018	2,198	176	283	308	N/A
9/30/2018	2,152	205	289	321	N/A
6/30/2018	2,041	248	N/A	185	N/A
3/31/2018	1,861	302	N/A	252	N/A
12/31/2017	1,751	320	N/A	356	N/A
9/30/2017	1,884	279	N/A	314	N/A
6/30/2017	1,937	266	N/A	377	N/A
3/31/2017	2,013	257	N/A	291	N/A
12/31/2016	2,103	250	N/A	240	N/A
9/30/2016	1,924	245	N/A	271	N/A
6/30/2016	1,893	238	N/A	117	N/A
3/31/2016	1,833	230	N/A	211	N/A
12/31/2015	1,784	223	N/A	183	N/A
9/30/2015	1,739	207	N/A	142	N/A
6/30/2015	1,657	215	N/A	197	N/A
3/31/2015	1,642	203	N/A	96	N/A
12/31/2014	1,621	201	N/A	112	N/A
9/30/2014	1,607	205	N/A	119	N/A
6/30/2014	1,623	199	N/A	90	N/A
3/31/2014	1,605	188	N/A	111	N/A
12/31/2013	1,602	186	N/A	130	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 600993 'nin tahmini kazanç büyümesi (yıllık 18.9% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 600993 şirketinin kazançlarının (yıllık 18.9% ) CN pazarından (yıllık 26.2% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 600993 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 600993 şirketinin gelirinin (yıllık 14.4% ) CN pazarından (yıllık 13.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 600993 şirketinin gelirinin (yıllık 14.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 600993 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 14.7 %).

Mayinglong Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.32 in 3Q 2023)

Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

Mayinglong Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.21 in 2Q 2023)

What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You

Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Dividend increased to CN¥0.40

Now 23% overvalued after recent price rise

Now 15% overvalued after recent price rise

Now 18% overvalued after recent price rise

Now 21% overvalued after recent price rise

Mayinglong Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet

Mayinglong Pharmaceutical Group Co., Ltd., Annual General Meeting, Jun 18, 2024

Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥1.11 in FY 2022)

Mayinglong Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel

Mayinglong Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

Third quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.34 in 3Q 2022)

New major risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.31 in 2Q 2022)

Mayinglong Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Full year 2022 earnings released: EPS: CN¥1.11 (vs CN¥1.08 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.26 in 3Q 2021)

Now 20% undervalued

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.32 in 2Q 2021)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.22 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.30 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.25 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.97 (vs CN¥0.84 in FY 2019)

Mayinglong Pharmaceutical Group Co., LTD. to Report Fiscal Year 2020 Results on Mar 26, 2021

Investor sentiment deteriorated over the past week

New 90-day low: CN¥19.37

Investor sentiment improved over the past week

New 90-day high: CN¥22.46

New 90-day low: CN¥20.34

Third quarter earnings released

Mayinglong Pharmaceutical Group Co., LTD. to Report Q3, 2020 Results on Oct 24, 2020

New 90-day low: CN¥20.92

Earnings released

Mayinglong Pharmaceutical Group Co., LTD. to Report First Half, 2020 Results on Aug 22, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin